Imiquimod-d6

Category	Herpes simplex Virus (HSV)
Description	Imiquimod-d6 (R 837-d6) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

Quotation Now

Synonyms	R 837-d6
Molecular Weight	246.34
Molecular Formula	C14H10D6N4
Canonical SMILES	NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C([2H])([2H])[2H])C([2H])([2H])[2H]
Purity	≥98% (HPLC)
Solubility	In vitro: 10 mM in DMSO
Appearance	Solid powder
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Complexity	294
Exact Mass	246.175157003
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs.
In Vivo	In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secretecytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α.
Target	Toll-like Receptor (TLR); Autophagy; SARS-CoV; HSV
XLogP3-AA	2.6